NCT06495957Not yet recruiting
Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease
Evaluation of Therapeutic Effect and Brain Mechanism of Electroacupuncture in Treating Agitation Symptoms of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 11 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy of electroacupuncture in the treatment of agitation symptoms in patients with Alzheimer's disease (AD). Meanwhile the study aims to explore the brain central mechanism of electroacupuncture in the treatment of agitation symptoms in patients with AD by using resting state functional magnetic resonance technology.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 224 (estimated)
- First submitted
- 3 Jul 2024
- Start date
- 20 Jul 2024
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Diseases
- Alzheimer disease
- NCT number
- NCT06495957
What you commit to
- Study type: Interventional
- Planned participants: 224
- From 20 Jul 2024 to the primary completion date, 31 Jul 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received electroacupuncture treatment in the past 2 weeks
Other illness
- There are contraindications for acupuncture treatment, such as the tendency of acupoint bleeding or allergy to metal
Other
- At the time of the screening, participants are participating in other clinical trials or planned to participate in other clinical trials in the next 17 weeks.
Who the study is looking for
- Meet the revised draft diagnostic criteria for Alzheimer's disease published by the Alzheimer's Association in 2023
- Meet the 2023 IPA definition of agitated symptoms of cognitive impairment
- Cohen Mansfield Agitation Inventory (CMAI)≥45 points
- Have been on stable anti-AD medication (cholinesterase inhibitors, etc.) for more than 1 month
- If taking antipsychotics, the medication regimen for agitation (antipsychotics) is stable for 1 month prior to randomization
- Subject and legal guardian and caregiver sign informed consent.
Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital of Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing United Family Rehabilitation Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing Geriatric Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| China-Japan Friendship Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Guang'anmen Hospital of China Academy of Chinese Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Fujian University of Traditional Chinese Medicine Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine Coordinator of this site? Confirm its status | Harbin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.